Loading...
In the continuum of Alzheimer disease (AD) symptomatology, amnestic types of mild cognitive impairment (MCI) represent preclinical stages, during which potentially disease-modifying AD drugs would produce greater benefits than in the general population. Identifying biomarkers for such high-risk states would allow accurate, noninvasive diagnosis of very early AD-type dysfunction and pathology. The apparent diffusion coefficient (ADC), calculated from DWI MRI data, might be one such marker.
To assess regional ADCs in gray and white matter (GWM) regions in MCI, researchers compared DWI group data between 13 patients with MCI (mean age, 74; mean MMSE score, 26.8) and 13 nondemented controls (mean age, 75; mean MMSE score, 28.6). The techniques i…